Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Adjuvant Therapy in Stage IIIc Gastric Cancer
NCT05769725Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised trial of serplulimab in gastric cancer (GC) (2 arms), sponsored by Renji Hospital. Primary endpoint: Disease-Free Survival at 1 year. Started Mar 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05769725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769725.